JP2023542930A5 - - Google Patents
Info
- Publication number
- JP2023542930A5 JP2023542930A5 JP2023518170A JP2023518170A JP2023542930A5 JP 2023542930 A5 JP2023542930 A5 JP 2023542930A5 JP 2023518170 A JP2023518170 A JP 2023518170A JP 2023518170 A JP2023518170 A JP 2023518170A JP 2023542930 A5 JP2023542930 A5 JP 2023542930A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- pharmaceutical composition
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082365P | 2020-09-23 | 2020-09-23 | |
| US63/082,365 | 2020-09-23 | ||
| PCT/US2021/051648 WO2022066835A1 (en) | 2020-09-23 | 2021-09-23 | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542930A JP2023542930A (ja) | 2023-10-12 |
| JP2023542930A5 true JP2023542930A5 (cg-RX-API-DMAC10.html) | 2024-10-01 |
| JP7856636B2 JP7856636B2 (ja) | 2026-05-11 |
Family
ID=80845797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518170A Active JP7856636B2 (ja) | 2020-09-23 | 2021-09-23 | セレブロンタンパク質のモジュレータとしての置換ｎ－（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－５－イル）アリールスルホンアミド類似体 |
Country Status (14)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022066835A1 (en) | 2020-09-23 | 2022-03-31 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| EP4554581A1 (en) | 2022-07-13 | 2025-05-21 | Monte Rosa Therapeutics AG | Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors |
| US20260014133A1 (en) * | 2022-07-15 | 2026-01-15 | St. Jude's Chidren's Research Hospital, Inc. | SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| WO2024073871A1 (en) * | 2022-10-04 | 2024-04-11 | Biofront Ltd | Gspt1 degraders, compositions comprising the degrader, and methods of using the same |
| CN117917402A (zh) * | 2022-10-21 | 2024-04-23 | 暨南大学 | 异吲哚酰胺类化合物及其药物组合物和应用 |
| WO2024109918A1 (zh) * | 2022-11-24 | 2024-05-30 | 西藏海思科制药有限公司 | 一种gspt1降解剂及其在医药上的应用 |
| KR102570883B1 (ko) * | 2023-04-13 | 2023-08-29 | (주) 사이러스테라퓨틱스 | 신규한 gspt1 분해제 및 이의 용도 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025067255A1 (zh) * | 2023-09-26 | 2025-04-03 | 映恩生物制药（苏州）有限公司 | 哌啶二酮类化合物、其制备方法和用途 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998023617A1 (en) | 1996-11-26 | 1998-06-04 | American Cyanamid Company | Hetero-biaryl-pyridoquinazolinone derivatives as anti-cancer agents |
| BR9714142A (pt) * | 1996-12-17 | 2000-02-29 | Warner Lambert Co | Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| PL371344A1 (en) * | 2002-02-13 | 2005-06-13 | Glaxo Group Limited | Benzenesulfonamide derivatives as antipsychotic agents |
| CA2822094C (en) | 2005-08-31 | 2015-10-27 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CN101578277A (zh) * | 2006-08-30 | 2009-11-11 | 细胞基因公司 | 5-取代的异二氢吲哚化合物 |
| AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| US7938952B2 (en) | 2008-05-20 | 2011-05-10 | Institute Francais Du Petrole | Process for multistage residue hydroconversion integrated with straight-run and conversion gasoils hydroconversion steps |
| CA2957226C (en) | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| JP5944823B2 (ja) | 2010-07-02 | 2016-07-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| UA116544C2 (uk) | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| CA2908954C (en) | 2013-04-17 | 2021-08-03 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| AU2016266942B2 (en) * | 2015-05-22 | 2018-10-18 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| EP3399980B1 (en) * | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| TWI782395B (zh) | 2016-01-08 | 2022-11-01 | 美商西建公司 | 抗增生化合物，及其醫藥組合物及用途 |
| SG11201809501PA (en) * | 2016-06-06 | 2018-12-28 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP4119552A1 (en) | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| CN108929307A (zh) | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| JP2019017801A (ja) | 2017-07-19 | 2019-02-07 | 株式会社島津製作所 | Ｘ線撮影装置 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| KR102129367B1 (ko) * | 2017-10-20 | 2020-07-03 | 한국화학연구원 | 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| CN118344338A (zh) | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| EP3820532A4 (en) | 2018-07-11 | 2022-04-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| US20240124459A9 (en) | 2020-06-29 | 2024-04-18 | Dana-Farber Cancer Institute, Inc. | Prpk inhibitors |
| IL301564A (en) | 2020-09-23 | 2023-05-01 | Transposon Therapeutics Inc | LINE-1 inhibitors to treat the disease |
| MX2023003362A (es) | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| WO2022066835A1 (en) | 2020-09-23 | 2022-03-31 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
-
2021
- 2021-09-23 WO PCT/US2021/051648 patent/WO2022066835A1/en not_active Ceased
- 2021-09-23 CN CN202180065415.5A patent/CN116209439B/zh active Active
- 2021-09-23 MX MX2023003114A patent/MX2023003114A/es unknown
- 2021-09-23 EP EP21873389.7A patent/EP4217352A4/en active Pending
- 2021-09-23 AU AU2021347238A patent/AU2021347238A1/en active Pending
- 2021-09-23 BR BR112023005344A patent/BR112023005344A2/pt unknown
- 2021-09-23 KR KR1020227017575A patent/KR102499522B1/ko active Active
- 2021-09-23 IL IL301588A patent/IL301588A/en unknown
- 2021-09-23 JP JP2023518170A patent/JP7856636B2/ja active Active
- 2021-09-23 PE PE2023001201A patent/PE20230847A1/es unknown
- 2021-09-23 CA CA3196278A patent/CA3196278A1/en active Pending
-
2022
- 2022-05-09 US US17/740,148 patent/US12454518B2/en active Active
-
2023
- 2023-02-07 CL CL2023000394A patent/CL2023000394A1/es unknown
- 2023-04-21 ZA ZA2023/04644A patent/ZA202304644B/en unknown
- 2023-09-14 US US18/368,497 patent/US12454519B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023254894A1 (en) | Combination therapy for treating cancer | |
| EP3303359B1 (en) | Nucleotides for the treatment of cancer | |
| US10076534B2 (en) | Effective treatment of ovarian cancer using triciribine and related compounds | |
| EP4085919A2 (en) | Compositions and methods to treat cancer | |
| US20180141939A1 (en) | Solid forms of a bet inhibitor | |
| EA032509B1 (ru) | Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| EP2880032B1 (en) | Aryl lactam kinase inhibitors | |
| KR20170005492A (ko) | 암의 치료를 위한 뉴클레오시드 유도체 | |
| EP3121175A1 (en) | 1,3-benzodioxole derivative | |
| EP4495115A1 (en) | Tetracyclic compound and use thereof | |
| EP3191592A1 (en) | Inhibition of prmt5 to treat mtap-deficiency-related diseases | |
| EA037871B1 (ru) | Производные азабензимидазола в качестве ингибиторов pi3k beta | |
| JP2020511131A5 (cg-RX-API-DMAC10.html) | ||
| CN119343142A (zh) | 治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法 | |
| EP3099300B1 (en) | Aryl lactam kinase inhibitors | |
| EP3952877A1 (en) | Heterocyclic compounds and uses thereof | |
| EP3541825A1 (en) | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | |
| US10815264B2 (en) | Nucleotides for the treatment of cancer | |
| JP2024517473A5 (cg-RX-API-DMAC10.html) | ||
| EP4241837B1 (en) | Nicotinamide mononucleotide derivatives in the treatment and prevention of polycythemia vera. | |
| BR9915448A (pt) | Derivados do ácido betulìnico, processos para preparar esses derivados e seu uso como inibidores do crescimento de câncer | |
| EP2991993B1 (en) | Morpholinyl anthracycline derivatives | |
| PT1406907E (pt) | Derivados antitumorais de et-743 | |
| JP2014505052A (ja) | 癌の治療および予防用の新規なウレア | |
| WO2022029287A1 (en) | Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity |